Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy With Intravitreal Injection of Lucentis (Ranibizumab Injection)

Trial Profile

Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy With Intravitreal Injection of Lucentis (Ranibizumab Injection)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Nov 2014

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Age-related macular degeneration; Choroidal neovascularisation; Choroiditis; Degenerative myopia; Retinal telangiectasis; Von Hippel-Lindau disease
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Aug 2014 New trial record
    • 24 Oct 2012
    • 29 May 2007
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top